Mark A Knepper Selected Research

Nephrogenic Diabetes Insipidus

1/2021	Phosphoproteomic Identification of Vasopressin/cAMP/Protein Kinase A-Dependent Signaling in Kidney.
1/2019	RNA-Seq and protein mass spectrometry in microdissected kidney tubules reveal signaling processes initiating lithium-induced nephrogenic diabetes insipidus.
1/2017	Roflumilast and aquaporin-2 regulation in rat renal inner medullary collecting duct.
10/2014	Early targets of lithium in rat kidney inner medullary collecting duct include p38 and ERK1/2.
10/2009	A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus.
4/2008	Treating lithium-induced nephrogenic diabetes insipidus with a COX-2 inhibitor improves polyuria via upregulation of AQP2 and NKCC2.
3/2008	Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation.
5/2006	Lithium-induced NDI in rats is associated with loss of alpha-ENaC regulation by aldosterone in CCD.
2/2006	Aldosterone increases urine production and decreases apical AQP2 expression in rats with diabetes insipidus.
11/2004	Antidiuretic effect of hydrochlorothiazide in lithium-induced nephrogenic diabetes insipidus is associated with upregulation of aquaporin-2, Na-Cl co-transporter, and epithelial sodium channel.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark A Knepper Research Topics

Disease

16	Polyuria 01/2019 - 01/2002
11	Nephrogenic Diabetes Insipidus 01/2021 - 12/2003
10	Ureteral Obstruction 07/2011 - 05/2003
7	Hypertension (High Blood Pressure) 05/2015 - 06/2002
5	Hyponatremia 01/2018 - 02/2001
4	Kidney Diseases (Kidney Disease) 03/2014 - 06/2008
4	Heart Failure 02/2014 - 01/2002
4	Fibrosis (Cirrhosis) 02/2014 - 02/2005
4	Ascites 03/2006 - 05/2004
3	Diabetic Nephropathies (Diabetic Nephropathy) 01/2018 - 06/2002
3	Hypercalcemia (Milk Alkali Syndrome) 03/2004 - 01/2002
2	Autosomal Dominant Polycystic Kidney (ADPKD) 01/2022 - 09/2004
2	Inappropriate ADH Syndrome (SIADH) 01/2018 - 01/2002
2	Hypokalemia 12/2012 - 06/2006
2	Polydipsia 10/2009 - 06/2006
2	Bartter Syndrome (Syndrome, Bartter) 02/2009 - 09/2004
2	Hydronephrosis 11/2008 - 06/2004
2	Gitelman Syndrome 06/2006 - 09/2004
2	Nephrotic Syndrome (Syndrome, Nephrotic) 03/2006 - 05/2004
2	Proteinuria 03/2006 - 05/2004
2	Hypoalbuminemia 03/2006 - 05/2004
2	Edema (Dropsy) 03/2006 - 05/2004
2	Diabetes Insipidus 02/2006 - 11/2004
2	Liver Cirrhosis (Hepatic Cirrhosis) 11/2005 - 02/2005
2	Hyperaldosteronism (Conn Syndrome) 02/2005 - 11/2003
1	Sickle Cell Anemia (Hemoglobin S Disease) 01/2019
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2019
1	Albuminuria 01/2018
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2017
1	Wounds and Injuries (Trauma) 09/2014
1	Necrosis 04/2014
1	Neurogenic Diabetes Insipidus (Central Diabetes Insipidus) 02/2014
1	Inflammation (Inflammations) 12/2012
1	Epilepsy (Aura) 05/2009
1	Alkalosis 05/2009
1	Deafness (Deaf Mutism) 05/2009
1	Ataxia (Dyssynergia) 05/2009
1	Atrophy 11/2008
1	Type 2 Diabetes Mellitus (MODY) 12/2007
1	Hyperglycemia 12/2007
1	Osteoporosis 09/2007
1	Carcinoma (Carcinomatosis) 07/2007
1	Hypertrophy 06/2007
1	Acidosis 01/2007
1	Paralysis (Palsy) 04/2006

Drug/Important Bio-Agent (IBA)

19	SodiumIBA 02/2009 - 02/2001
13	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2003
12	Vasopressins (Vasopressin)IBA 01/2021 - 02/2001
11	Aquaporins (Water Channels)IBA 01/2018 - 12/2002
10	LithiumIBA 01/2021 - 12/2003
10	Aquaporin 2IBA 01/2019 - 05/2003
7	AldosteroneIBA 06/2006 - 12/2002
6	SaltsIBA 01/2019 - 06/2002
6	Epithelial Sodium ChannelsIBA 12/2007 - 05/2003
4	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 01/2017 - 01/2004
3	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2018
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 06/2008
3	ThiazidesIBA 09/2007 - 11/2004
2	Urea (Carbamide)FDA LinkGeneric 01/2019 - 06/2004
2	ProteomeIBA 01/2018 - 06/2008
2	DiureticsIBA 05/2015 - 06/2007
2	Pharmaceutical PreparationsIBA 09/2014 - 09/2007
2	AntibodiesIBA 03/2014 - 02/2005
2	Angiotensin IIIBA 12/2009 - 05/2003
2	Antidiuretic AgentsIBA 04/2008 - 11/2004
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 04/2008 - 11/2006
2	candesartanIBA 11/2006 - 05/2003
2	SymportersIBA 11/2005 - 11/2004
2	Carrier Proteins (Binding Protein)IBA 08/2005 - 06/2004
2	Vitamin D FDA LinkGeneric 12/2002 - 01/2002
1	Cyclic AMP (AMP, Cyclic)IBA 01/2022
1	Adenosine Monophosphate (AMP)IBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2021
1	N- (2- (4- bromocinnamylamino)ethyl)- 5- isoquinolinesulfonamide (h89)IBA 01/2021
1	Sodium-Potassium-Chloride SymportersIBA 01/2019
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2018
1	Neprilysin (Neutral Endopeptidase)IBA 01/2018
1	RoflumilastIBA 01/2017
1	Cyclic NucleotidesIBA 01/2017
1	Phosphodiesterase InhibitorsIBA 01/2017
1	satavaptanIBA 02/2014
1	Neurophysins (Neurophysin I)IBA 02/2014
1	Membrane Proteins (Integral Membrane Proteins)IBA 07/2011
1	Dinoprostone (PGE2)FDA Link 10/2009
1	K Cl- CotransportersIBA 02/2009
1	Contrast MediaIBA 11/2008
1	5-methoxy-methylindoleacetic acid (DBI)IBA 06/2008
1	ProstaglandinsIBA 04/2008
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 04/2008
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 04/2008
1	Glucose (Dextrose)FDA LinkGeneric 12/2007
1	Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA 09/2007
1	Antihypertensive Agents (Antihypertensives)IBA 09/2007
1	Proton-Translocating ATPases (ATPase, H+)IBA 06/2007
1	Messenger RNA (mRNA)IBA 01/2007
1	PotassiumIBA 06/2006
1	Dietary PotassiumIBA 06/2006
1	Lidocaine (Xylocaine)FDA LinkGeneric 04/2006
1	PlacebosIBA 04/2006

Therapy/Procedure

1	Ligation 12/2009